Consistent with these findings, the IMpower150 trial in NSCLC reported that a T‐effector (Teff) gene expression signature, composed of PD‐L1, CXCL9, and IFN‐γ, enriched for PFS benefit when comparing atezolizumab plus chemotherapy with chemotherapy [18]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.